血清OPG与冠心病的相关性及阿托伐他汀干预效果研究
|
摘要
目的：①探讨不同类型的冠状动脉性心脏病(CHD)患者血清中骨保护素(OPG)和超敏C反应蛋白(hs-CRP)的水平,及其与冠状动脉病变程度的关系。②冠心病患者在使用阿托伐他汀钙片干预前后血清骨保护素(OPG)、超敏C反应蛋白(hs-CRP)水平的变化情况。
方法：选取入住我院心内科的患者，按疾病严重程度分为急性冠脉综合征（ACS）组（n=30例）、稳定性心绞痛（SA）组(n=30例)及对照组（CO）组(n=10例)，检测并比较3组患者的血清中骨保护素（OPG）和超敏C反应蛋白（hs-CRP）表达水平的差异。其表达水平再与冠脉造影结果进行比对和分析。所有入选患者在给予阿托伐他汀钙片（20mg，一次/日）2周后再次检测3组患者血清OPG、hs-CRP的表达水平，并分析给药前后二者表达水平的差异。
结果：①ACS组患者的血清OPG及hs-CRP表达水平明显高于SA组及CO组，而SA组血清OPG及hs-CRP的表达水平又高于CO组(P<0.01)，且血清中OPG与hs–CRP的含量均随着冠脉病变数目的增加而增高。②在冠心病患者的血清中，OPG水平的变化同hs-CRP水平呈正相关(r=0.875,P<0.01)。③在服用阿托伐他汀钙片2周后ACS组患者血清中OPG及hs-CRP表达水平较服药前明显降低，差别有统计学意义(P<0.05)；SA组血清hs-CRP下降也有统计学意义，而SA组患者中血清OPG水平有所下降，但变化无统计学意义(P＞0.05)；对照组血清OPG及hs-CRP变化均无统计学意义。
结论：冠状动脉性心脏病患者的血清OPG表达水平随冠心病严重程度增加而升高,且与hs-CRP水平呈正相关,提示OPG系统可能通过干预血管炎症反应而参与了冠状动脉粥样硬化病变进程。应用阿托伐他汀的治疗明显降低了ACS组患者血清中OPG、hs-CRP的表达水平。
Objective:①To analyses the relationship between the levels of serum osteoproteger (OPG), hyper sensitive C reactive protein (hs-CRP) and severity of coronary artery lesions.②Before and after Coronary heart disease patients taking atorvastatin, serum osteoproteger (OPG) and high sensitivity C-reactive protein (hs-CRP)change in the level.
Methods:According pathogenetic condition,60cases of patients with CHD were divided into acute coronary syndrome groups (ACS)(30cases), stable angina pectoris groups(SA)(30cases)and control groups (CO)(10cases), the level of OPG and hs-CRP in serum were detected with enzyme linked immunosorbent assay way. the difference of expressiving and the resulting coronary angiography were contrasted. All patients were given atorvastatin calcium (20mg/day). after two weeks, the three groups of patients with expression levels of serum of OPG and hs-CRP was detected again.And analyze the differences in the levels of expression before and after drug delivery.
Result:①The levels of Serum OPG and hs-CRP were significantly higher in ACS group than those in SA group and controls group (P<0.01). The levels of Serum OPG and hs-CRP was higherin SA group than the CO group (P<0.01). As the numbers o f diseased vessels increased, there was a significant increasing in serum OPG and hs-CRP levels (P<0.01).②A positive relation was found between OPG and hs-CRP (r=0.875, P<0.01). After two weeks of taking atorvastatin calcium, serum OPG and hs-CRP in patients with ACS significantly decreased, there are statistically significant (P<0.05). The decreasing of serum hs-CRP have also statistically significant in SA group,serum OPG levels decline in the SA group, but the changes was not statistically significant (P>0.05); the changes of serum OPG and hs-CRP were not statistically significant in control group.
Conclusion:The levels of serum OPG and hs-CRP are associated with the stenosis degree of the coronary artery in patients with acute coronary syndrome. OPG system were involved in the process of coronary atherosclerotic lesionsmay through interfereing with vascular inflammation reaction. Atorvastatin calcium significantly reduces the serum of OPG and hs-CRP levels of patients with ACS.
方法：选取入住我院心内科的患者，按疾病严重程度分为急性冠脉综合征（ACS）组（n=30例）、稳定性心绞痛（SA）组(n=30例)及对照组（CO）组(n=10例)，检测并比较3组患者的血清中骨保护素（OPG）和超敏C反应蛋白（hs-CRP）表达水平的差异。其表达水平再与冠脉造影结果进行比对和分析。所有入选患者在给予阿托伐他汀钙片（20mg，一次/日）2周后再次检测3组患者血清OPG、hs-CRP的表达水平，并分析给药前后二者表达水平的差异。
结果：①ACS组患者的血清OPG及hs-CRP表达水平明显高于SA组及CO组，而SA组血清OPG及hs-CRP的表达水平又高于CO组(P<0.01)，且血清中OPG与hs–CRP的含量均随着冠脉病变数目的增加而增高。②在冠心病患者的血清中，OPG水平的变化同hs-CRP水平呈正相关(r=0.875,P<0.01)。③在服用阿托伐他汀钙片2周后ACS组患者血清中OPG及hs-CRP表达水平较服药前明显降低，差别有统计学意义(P<0.05)；SA组血清hs-CRP下降也有统计学意义，而SA组患者中血清OPG水平有所下降，但变化无统计学意义(P＞0.05)；对照组血清OPG及hs-CRP变化均无统计学意义。
结论：冠状动脉性心脏病患者的血清OPG表达水平随冠心病严重程度增加而升高,且与hs-CRP水平呈正相关,提示OPG系统可能通过干预血管炎症反应而参与了冠状动脉粥样硬化病变进程。应用阿托伐他汀的治疗明显降低了ACS组患者血清中OPG、hs-CRP的表达水平。
Objective:①To analyses the relationship between the levels of serum osteoproteger (OPG), hyper sensitive C reactive protein (hs-CRP) and severity of coronary artery lesions.②Before and after Coronary heart disease patients taking atorvastatin, serum osteoproteger (OPG) and high sensitivity C-reactive protein (hs-CRP)change in the level.
Methods:According pathogenetic condition,60cases of patients with CHD were divided into acute coronary syndrome groups (ACS)(30cases), stable angina pectoris groups(SA)(30cases)and control groups (CO)(10cases), the level of OPG and hs-CRP in serum were detected with enzyme linked immunosorbent assay way. the difference of expressiving and the resulting coronary angiography were contrasted. All patients were given atorvastatin calcium (20mg/day). after two weeks, the three groups of patients with expression levels of serum of OPG and hs-CRP was detected again.And analyze the differences in the levels of expression before and after drug delivery.
Result:①The levels of Serum OPG and hs-CRP were significantly higher in ACS group than those in SA group and controls group (P<0.01). The levels of Serum OPG and hs-CRP was higherin SA group than the CO group (P<0.01). As the numbers o f diseased vessels increased, there was a significant increasing in serum OPG and hs-CRP levels (P<0.01).②A positive relation was found between OPG and hs-CRP (r=0.875, P<0.01). After two weeks of taking atorvastatin calcium, serum OPG and hs-CRP in patients with ACS significantly decreased, there are statistically significant (P<0.05). The decreasing of serum hs-CRP have also statistically significant in SA group,serum OPG levels decline in the SA group, but the changes was not statistically significant (P>0.05); the changes of serum OPG and hs-CRP were not statistically significant in control group.
Conclusion:The levels of serum OPG and hs-CRP are associated with the stenosis degree of the coronary artery in patients with acute coronary syndrome. OPG system were involved in the process of coronary atherosclerotic lesionsmay through interfereing with vascular inflammation reaction. Atorvastatin calcium significantly reduces the serum of OPG and hs-CRP levels of patients with ACS.
引文
[1]陆再英,钟南山,谢毅,等.动脉粥样硬化和冠状动脉粥样硬化性心脏病见：内科学[M].第7版.北京：人民卫生出版社,2008.267-268[2]GoanK. Hansson inflammation, Atherosclerosis, and Coronary Artery Disease. NEngl J MED,2005,352:1685-95.[3]杨胜利,何秉贤.C反应蛋白和冠心病[J].中华心血管杂志,2001,29(3)：187.[4]Abbate A, Biondi-ZoccaiG G, Brugaletta S, et al C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes syndromes [J]. Semin Vase Med,2003,(4):375-384[5]DooYC, HanSJ, ParkWJ, etal. Assoeiations between C-reactive proteinand circulating cell adhesion molecules in patients with unstable angina undergoing coronary inter-vention and their clinical implication. Clin Cardiol,2005,28:47-51.[6]张立.C-反应蛋白与急性冠脉综合征.国外医学临床生物化学与检验学分册,2003,24(5)：260-261.[7]Rettersto L, EikvarL, BohnM, etal. C-reactive protein predicts death in patients with previous premature myocardial infarction-a10years follow-up study Atherosclerosis,2002,160:433-440.[8]ZannettinoAC, HoldingCA, DiamondP, etal. Osteprotegerin(OPG) is loealized to the Weibel-Palade bodies of human vascular endothelial cells and is physically assoeiated with von Wiilebrand factor.J Cell Physiol,2005,204:714-723.[9]Brian J.Bennett, MartaSeatena, ElizabethA. etal. Osteoprotegerin Inactivation Accelerates Advanced Atheroselerotic Lesion Progression and Caleifieationin OlderApoE-/-Mice. Arterioseler. Thromb. Vase. Biol.2006,26(9):2117-2124.[10]AvignonA, Sultan A, PiotC, et al Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type2diabetic patients [J] Diabetes Care,2005,28(9):2176-2180.[11]Crisafulli A, Micari A, Altavilla D, et al Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction Clin Sci (Lond),??2005,109(4):3892-3951.[12]Shuichi J, Yuji I, At sushi S, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease Circulation,2002,9:1192-1194.[13]Andrea Dovio, Barbara Allasino, Enrico Palmas, et al. Increased Osteoprotegerin Levels in Cushing's Syndrome Are Associated with an Adverse Cardiovascular Risk Pr ofile [J]. J Clin Endocrinol Metab,2007,92(5):1803-1808.[14]Price PA, June HH,Buckley JR, et al. Osteoprotegerin inhibts artery calcification induced by warfarin and by vitamin D.[J].Arterioscler Thromb Vasc Biol,2001,21(10):1610-1616.[15]Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experiment al heart failure [J]. Circulation,2005,111:2461-2468[16]赵水平.他汀类药物抗炎防冶动脉粥样硬化.中华医学杂志,200585：2818-2819[17]黄宇.他汀类药物对舒张性心衰的分子生物学机制国际心血管病杂志。2007.34：60-62.[18]严毓勤.胡靖超,吴士尧他汀类药物早期干预对急性冠脉综合征患者舢自高敏C反应蛋白和纤维蛋白原的影响.上海医学.2003.26：645-647.[19]Palazzuoli A, Rizzello V,Calabro A,et al. Osteoprotegerin and B type natriuretic peptide in non-ST elevation acute coronary syndromes:relation to coronary artery narrowing and plaques number [J]. Clin Chim Acta,2008,391(1-2).[20]Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of steoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption [J]. J Bone Miner Res,2000,15(1):2-12.[21]Olga Ovchinnikova,Asa Gylfe, Leslie Bailey, et al. Osteoprotegerin Promotes Fibrous Cap Formation in Atherosclerotic Lesions of ApoE-Deficient Mice[J]. Arterioscler Thromb Vase Biol,2010,30(5):1066-1068.[22]Yano K,Tsuda E,Washida N,et al.Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor:increased serum??concentrations in postmenopausal women with osteoporosis.J Bone Miner Res,1999,14:518-527.[23]Zannettino AC, Holding CA, Diamon dP, etal. Osteprotegerin(OPG) localized to the the Weibel-Palade bodies of human vascular endothelial cells and is physically assoeiated with von Wiilebrand factor.J Cell Physiol,2005,204:714-723.[24]Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin:a novel secreted protein involved in the regulation of bone density.Cell,1997,89(2)309-319.[25]Browner WS, Lui LY, Cummings SR. Association of serum osteoprotegerin levels with diabetes, stroke, bone density,fractures, and mortality in elderly women. J Clin Endocrinol Met ab,2001,86(2):631-637.[26]ROTH E L, ANDERSON F, NELSON M, et al. Receptor activator of NF-kB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclasto genesis[J]. J Bio1Chem,2001,37(6):20659-20672.[27]ZHANG J, FU M, MYLES D, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways [J]. FEBS Lett,2002,52(1),180-184.[28]H OFBAUER L, CANDSCHOPPET M. Clinical implications of the o steoprotegerin/RANKL/RANK system for bo ne and vascular diseases[J]. JAMA,2004,29(2),490-449.[29]Schwartz EA, Reaven PD Molecular and signaling mechanisms of atherosclerosis in insulin resistance[J]. Endocrinol Metab Clin North Am,2006,27(3):781-787[30]H OFBAUER L, CANDSCHOPPET M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases[J].JAMA,2004,29(2),490-449.[31]Ridker PM, Morrow D High-sensitivity C-reaction protein and cardiovascular risk:rationale for screening and primary prevention [J].Am J Cardiol,2003,92(Supple):17-22.[32]Keller T, Messow CM.Lubos E, etal. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normalor mildly reduced kidney function:results from the Athero Gene study. Eur Heart J,2009,30(3):314-320.[33]吴喻霞.超敏C反应蛋白含量和冠心病的关系[J].江西医学检验,2004,22(5)：4422443.[34]侯晓霞,贾三庆,王吉云.高敏C反应蛋白检测与冠心病[J].中国医药导刊,2002,4(3)：1772179.[35]Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions or human coronary arteries [J]. Arterioscler Thromb Vase Biol,1998,18:1386-1392.[36]DANIEL G, H ACKAM M D, SONIA S. Emerging risk fact ors for atherosclerotic vascular disease [J] JAMA,2003,29(3):932-939.[37]GOLDSTEIN J A, CHANDRA H R, O'NEILL WW. Relation of number of complex coronary lesions to serum C-reactive protein levels and major adverse cardiovascular events at one year [J]. Am J Car diol,2005,48(9):9656-9660.[38]胨国伟,血脂异常与冠D病中国实用内科杂志,2004.2A：261-262.[39]李大柱,SharmaRanjit,曾秋棠等阿托伐他汀对不稳定心绞痛患者树突状细胞功能的影响中华内科杂志,260443：429-432.[40]Clements JD, Jamali F. Pmvastatin reverses the down-regulating effect of inflammation on beta-Adrenersic receptors:A disease-drug interaction between inflammation, pravastatin, and propranolol. Vascul Pharmac01.2007.46(1):52-59.[41]ParkSY, LeeJS, KoYJ, etal. Inhibitory effect of simvastatin on the TNF-alpha and angiotensin Ⅱ-induced monocyte adhesion to endothelial cells is mediated tlirough the suppression of geranylgerany lisoPrenoid-dependent ROS genertion. Arch Phann Res,2008,31:195-204.1. Jono S, Ikari Y, Shioi A, et al. Serum osteop rotegerin levels are associated with the p resence and severity of coronary arter disease [J]. Circulation,2002,106(10):1192-1194.2. Torbjorn Oml, Thor Ueland, Anna M, et al. circulating Osteop rote-gerin Levels and Long-Term Prognosis in Patients With Acute Coronary Syndromes [J]. J Am Coll Cardiol,2008,51:627-633.3. Rukshana C, Shroff, John Deanfield, et al. The circulating calcification inhibitors, fetuin-A and osteop rotegerin, but not Matrix Glap rotein, are associated with vascular stiffness and calcificationin children on dialysis[J]. Nephrol Dial,2008,23:3263-3271.4. Yuichi Orita, Hideya Yamamoto, Nobuoki Kohno, et al. Role of Osteop rotegerin in Arterial Calcification Development of New Animal Model [J]. Arterioscler Thromb Vasc Biol,2007,27:2058-20645. Yun T J, Chaudhary PM, Shu GL, et al. OPG/FDCR21, a TNF receptor family member, is expressed in lymphoid cells and is up regulated by ligating CD40. J Immunol,1998,161:611326122.6. Hofbauer LC, Khosla S, Dunst an CR, et al. T he role of ost eoprot egerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res,2000,15:2212.7. Bucay N, Sarosi I, Dunstan CR, et al. Ost eoprot egerine deficientmice develop early onset ost eoporosis and art erial calcificat ion. Genes Dev,1998,12:126021268.8. Min H, Morony S, Sarosi I, et al. Ost eoprot egerin reverses ost eoporosis by inhibiting en dost eal ost eoclasts and prevents vascular calcificat ion by blocking a process resembling osteoclastogenesis. JExp Med,2000,192:4632474.9. Malyankar UM, Scat ena M, Suchland KL, et al. Ost eoprot egerin is an alpa vbet a induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem,2000,275:20959220962.10. Shuichi J, Yuji I, At sushi S, et al. Serum ost eoprot egerin levels are associated with the presence and severity of coronary artery disease. Circulation,2002,9:119221194.11. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of ost eoclastogenesis, lymphocyt e development and lymphe node organogenesis. Nature,1999,14:5182527.12. Vaccarezza M, Bortul R, Fadda R, et al. Increased OPG exp ression and impaired OPG/TRA IL ratio in the aorta of diabetic rats [J]. Med Chem,2007,3(4)3872391.13. Secchiero P, Corallini F, Pandolfi A, et al. An increased osteop rotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dys function[J]. Am J Pathol,2006,169(6):223622244.14. Browner WS,Lui LY, Cummings SR. Association of serum osteop rotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women [J]. Clin Endocrinol Metab,2001,86(2):6312637.15.张春炳,朱健.动脉粥样硬化与慢性炎症[J].中国临床保健杂志,2007,10(2)：206-208.16.胨国伟,血脂异常与冠D病中国实用内科杂志,2004.2A：261-262.17.胡下一.综合控制心血管多重危险因素的新思路中华内科杂志,2003A2：58718.赵敏,王钢,何军.氟伐他汀对急性冠状动脉综台征患者血清c—反应蛋白的影响中华心血管病杂志,200432：824-825.